Search

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Vaccines

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia

We get data science

Data scientists and engineers at Boehringer don't have to field the usual ill-conceived questions and comments. Here's their guide on what not to say!

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Veterinary Public Health

Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US

Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

GPP

Generalized Pustular Psoriasis (GPP) is a rare, lifelong skin disease, which may be life-threatening if left untreated.

AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers